Altamira Therapeutics Ltd. (CYTO)

Altamira Therapeutics Cash Flow Statement

Financials in millions CHF. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Net Income	-3.87	-26.53	-17.06	-8.2	-6.63	-11.5	-24.41	-30.66	-29.71	-18.19	Upgrade
Depreciation & Amortization	0.12	0.12	0.08	0.02	0.03	0.07	0.12	0.1	0.09	0.07	Upgrade
Share-Based Compensation	0.38	0.34	1.21	0.37	0.23	0.03	0.35	0.29	0.31	0.27	Upgrade
Other Operating Activities	-8.14	17.38	2.1	2.97	-2.02	-1.84	-0.34	0.82	0.57	-1.48	Upgrade
Operating Cash Flow	-11.51	-8.68	-13.67	-4.84	-8.39	-13.23	-24.28	-29.45	-28.73	-19.32	Upgrade
Capital Expenditures	0	0	0	0	-0.06	0.07	-0.01	-0.24	-0.08	-0.11	Upgrade
Acquisitions	1.43	0	0	0	0	0	0	0	0	0	Upgrade
Change in Investments	0.01	0	-0.18	0	0	0	0	0	0	0	Upgrade
Other Investing Activities	0	-2.14	-3.33	-2.31	-2.94	-1.89	-0.09	0.07	0.04	-1.07	Upgrade
Investing Cash Flow	1.44	-2.14	-3.51	-2.31	-3	-1.82	-0.1	-0.18	-0.04	-1.19	Upgrade
Share Issuance / Repurchase	10.51	3.96	6.84	16.07	9.79	17.45	13.04	0	21.13	50.29	Upgrade
Debt Issued / Paid	1.05	5.92	-0.07	1.52	-1.46	-9.27	-2.09	11.99	0	0	Upgrade
Other Financing Activities	-0.93	-0.05	-0.16	-0.64	-0.95	-2.44	-2.73	-0.55	-0.21	-0.68	Upgrade
Financing Cash Flow	10.62	9.83	6.61	16.96	7.38	5.73	8.22	11.44	20.92	49.61	Upgrade
Exchange Rate Effect	0.05	0.02	0.29	0.07	0.01	-0.26	-1.32	0.4	1.15	3.96	Upgrade
Net Cash Flow	0.56	-0.99	-10.56	9.8	-4.02	-9.32	-16.15	-18.19	-7.85	29.11	Upgrade
Free Cash Flow	-11.51	-8.68	-13.67	-4.84	-8.46	-13.16	-24.28	-29.7	-28.81	-19.43	Upgrade
Free Cash Flow Per Share	-28.94	-203.54	-400.87	-382.95	-1804.37	-21770.42	-56585.80	-69258.40	-71350.54	-56129.41	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).